, 8% (95%CI 48.7-96.6; Log-rank p = 0.458) for optic neuritis and transverse myelitis, and 44.4% (95%CI 19.6-79.6; Log-rank p = 0.617) for encephalopathy/brainstem syndrome. (B) Time to NMOSD-like phenotype conversion according to clinical phenotype at the onset. The 2-year risk to NMOSD-like phenotype conversion was 17, Figure S1. (A) Kaplan-Meier estimation of time to first relapse, according to clinical phenotype at the onset. The 2-year risk of the first relapse was 70.7% (95%CI 60.7-80.1) for optic neuritis (reference), vol.2, pp.64-95
, AQP4: Aquaporin-4; ARR: Annualised relapse rates
, CBA: Cell-based assay; CNS: Central nervous system
, CYC: Cyclophosphamide; EDSS: Expanded Disability Status Scale; IS: Immunosuppressants; IVIG: Intravenous immunoglobulins; MADEM: Multiphasic acute disseminated encephalomyelitis; MiTX: Mitoxantrone; MMF: Mycophenolate mophetil, CSF: Cerebrospinal fluid
, MOG: Myelin oligodendrocyte glycoprotein; MRI: Magnetic resonance imaging; MS: Multiple sclerosis; MS-DMD: MS disease-modifying drugs
, MTX: Methotrexate; NMOSD: Neuromyelitis optica spectrum disorders
, OCB: Oligoclonal bands; ON: Optic neuritis; PS: Propensity score
, RTX: Rituximab; SD: Standard deviation; TM: Transverse myelitis; VA: Visual acuity Faculté de Médecine Lyon-Est
, Observatoire Francais de la Sclérose En Plaques (OFSEP), Hôpital Pierre-Wertheimer
, APHP, issue.7
, Hôpital Pasteur, vol.2
, Centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM)
Neuromyelitis optica spectrum disorders with aquaporin-4 and myelinoligodendrocyte glycoprotein antibodies: a comparative study, JAMA Neurol, vol.71, pp.276-83, 2014. ,
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders, Neurology, vol.82, pp.474-81, 2014. ,
Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children, Neurol Neuroimmunol Neuroinflammation, vol.2, p.81, 2015. ,
Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease, Mult Scler, vol.21, pp.866-74, 2015. ,
Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome, Neurology, vol.89, pp.900-908, 2017. ,
Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis, Brain, vol.140, pp.617-644, 2017. ,
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing, J Neuroinflammation, vol.15, p.134, 2018. ,
Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes, J Neurol, vol.263, pp.1349-60, 2016. ,
Clinical presentation and prognosis in MOG-antibody disease: a UK study, Brain, vol.140, pp.3128-3166, 2017. ,
Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS, Neurol Neuroimmunol Neuroinflammation, vol.2, p.163, 2015. ,
Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease, JAMA Neurol, vol.75, pp.65-71, 2017. ,
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin, J Neuroinflammation, vol.13, p.279, 2016. ,
Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study, Neurology, vol.90, pp.1858-69, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01919569
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders, J Neuroinflammation, vol.8, p.184, 2011. ,
MOGIgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement -frequency, presentation and outcome, J Neuroinflammation, vol.13, p.281, 2016. ,
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome, J Neuroinflammation, vol.13, p.280, 2016. ,
Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease, JAMA Neurol, vol.75, pp.478-87, 2018. ,
Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination, J Neurol Neurosurg Psychiatry, vol.89, pp.127-164, 2017. ,
Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus, Neurol Neuroimmunol Neuroinflammation, vol.3, p.225, 2016. ,
EFNS guidelines on diagnosis and management of neuromyelitis optica, Eur J Neurol, vol.17, pp.1019-1051, 2010. ,
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS), J Neurol, vol.261, pp.1-16, 2014. ,
Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis, Stat Med, vol.35, pp.5642-55, 2016. ,
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples, Stat Med, vol.28, pp.3083-107, 2009. ,
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, vol.85, pp.177-89, 2015. ,
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann Neurol, vol.69, pp.292-302, 2011. ,
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions, Mult Scler, vol.19, pp.1261-1268, 2013. ,
Neuromyelitis optica and neuromyelitis optica spectrum disorders, Curr Opin Neurol, vol.30, pp.208-223, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01798528
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies, Nat Rev Neurol, vol.10, pp.493-506, 2014. ,
MOGantibody-related disorders: common features and uncommon presentations, J Neurol, vol.264, pp.1945-55, 2017. ,
Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica, Neurology, vol.77, pp.659-66, 2011. ,
Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder, JAMA Neurol, vol.71, p.1372, 2014. ,
Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders, Mult Scler, vol.23, pp.1377-84, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01798528
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab, Neurology, vol.76, pp.1310-1315, 2011. ,
Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability, J Neurol, vol.262, pp.2329-2364, 2015. ,
Efficacy of rituximab in refractory neuromyelitis optica, Mult Scler, vol.22, pp.955-964, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01889926
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders, JAMA Neurol, vol.73, p.1342, 2016. ,
Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis, Neurol Neuroimmunol Neuroinflammation, vol.3, p.257, 2016. ,
Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers, Arch Neurol, vol.67, pp.1016-1023, 2010. ,
Poor responses to interferon-beta treatment in patients with neuromyelitis optica and multiple sclerosis with long spinal cord lesions, PLoS One, vol.9, p.98192, 2014. ,
Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab, J Neurol Sci, vol.339, pp.223-228, 2014. ,
New natural history of interferon-?-treated relapsing multiple sclerosis, Ann Neurol, vol.61, pp.300-306, 2007. ,
, Publisher's Note
, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations